Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

L. Antunes, M. Rojas-Castro, M. Lozano, I. Martínez-Baz, I. Leroux-Roels, ML. Borg, B. Oroszi, M. Fitzgerald, R. Dürrwald, L. Jancoriene, A. Machado, G. Petrović, M. Lazar, L. Součková, S. Bacci, J. Howard, N. Verdasca, L. Basile, J. Castilla, S....

. 2025 ; 19 (3) : e70081. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009605

Grantová podpora
ECDC/2021/016 (EU-H) European Centre for Disease Prevention and Control

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.

Cantacuzino National Military Medical Institute for Research and Development Bucharest Romania

Center for Vaccinology Ghent University and Ghent University Hospital Ghent Belgium

Clinic of Infectious Diseases and Dermatovenerology Institute of Clinical Medicine Medical Faculty Vilnius University Vilnius Lithuania

Consortium for Biomedical Research in Epidemiology and Public Health Madrid Spain

Croatian Institute of Public Health Zagreb Croatia

Department of Infection Control Ghent University Hospital Ghent Belgium

Department of Infectious Diseases Lithuanian University of Health Sciences Kaunas Lithuania

Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest Romania

Epiconcept Paris France

Epidemiology Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal

European Centre for Disease Prevention and Control Stockholm Sweden

Health Service Executive Health Protection Surveillance Centre Dublin Ireland

Infectious Disease Prevention and Control Unit Health Promotion and Disease Prevention Msida Malta

Infectious Diseases Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal

Instituto de Salud Pública de Navarra IdiSNA Pamplona Spain

National Centre for Epidemiology Institute of Health Carlos 3 Madrid Spain

National Laboratory for Health Security Epidemiology and Surveillance Centre Semmelweis University Budapest Hungary

National Reference Centre for Influenza Robert Koch Institute Berlin Germany

Sub Directorate General of Surveillance and Response to Public Health Emergencies Public Health Agency of Catalonia Generalitat of Catalonia Barcelona Spain

University Hospital Brno Masaryk University Brno Czechia

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009605
003      
CZ-PrNML
005      
20250429135124.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/irv.70081 $2 doi
035    __
$a (PubMed)40059069
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Antunes, Liliana $u Epiconcept, Paris, France $1 https://orcid.org/0000000304535304
245    10
$a Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024 / $c L. Antunes, M. Rojas-Castro, M. Lozano, I. Martínez-Baz, I. Leroux-Roels, ML. Borg, B. Oroszi, M. Fitzgerald, R. Dürrwald, L. Jancoriene, A. Machado, G. Petrović, M. Lazar, L. Součková, S. Bacci, J. Howard, N. Verdasca, L. Basile, J. Castilla, S. Ternest, A. Džiugytė, G. Túri, R. Duffy, C. Hackmann, M. Kuliese, V. Gomez, ZL. Makarić, A. Marin, P. Husa, N. Nicolay, AMC. Rose, VEBIS SARI VE network team
520    9_
$a We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    12
$a COVID-19 $x prevence a kontrola $x epidemiologie $x imunologie $7 D000086382
650    12
$a SARS-CoV-2 $x imunologie $7 D000086402
650    12
$a vakcíny proti COVID-19 $x imunologie $x aplikace a dávkování $7 D000086663
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a účinnost vakcíny $7 D000087507
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a vakcinace $x statistika a číselné údaje $7 D014611
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rojas-Castro, Madelyn $u Epiconcept, Paris, France $1 https://orcid.org/0000000170067946
700    1_
$a Lozano, Marcos $u National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
700    1_
$a Martínez-Baz, Iván $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain $u Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain
700    1_
$a Leroux-Roels, Isabel $u Department of Infection Control, Ghent University Hospital, Ghent, Belgium $u Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium
700    1_
$a Borg, Maria-Louise $u Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta
700    1_
$a Oroszi, Beatrix $u National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000189150336
700    1_
$a Fitzgerald, Margaret $u Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland
700    1_
$a Dürrwald, Ralf $u National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany $1 https://orcid.org/0000000234320438
700    1_
$a Jancoriene, Ligita $u Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania
700    1_
$a Machado, Ausenda $u Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal
700    1_
$a Petrović, Goranka $u Croatian Institute of Public Health, Zagreb, Croatia
700    1_
$a Lazar, Mihaela $u Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania
700    1_
$a Součková, Lenka $u University Hospital Brno, Masaryk University, Brno, Czechia
700    1_
$a Bacci, Sabrina $u European Centre for Disease Prevention and Control, Stockholm, Sweden
700    1_
$a Howard, Jennifer $u Epiconcept, Paris, France
700    1_
$a Verdasca, Nuno $u Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal
700    1_
$a Basile, Luca $u Sub-Directorate General of Surveillance and Response to Public Health Emergencies, Public Health Agency of Catalonia, Generalitat of Catalonia, Barcelona, Spain
700    1_
$a Castilla, Jesús $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain $u Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain $1 https://orcid.org/0000000263967265
700    1_
$a Ternest, Silke $u Department of Infection Control, Ghent University Hospital, Ghent, Belgium
700    1_
$a Džiugytė, Aušra $u Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta
700    1_
$a Túri, Gergő $u National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary
700    1_
$a Duffy, Roisin $u Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland
700    1_
$a Hackmann, Carolin $u National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany
700    1_
$a Kuliese, Monika $u Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania
700    1_
$a Gomez, Verónica $u Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal
700    1_
$a Makarić, Zvjezdana Lovrić $u Croatian Institute of Public Health, Zagreb, Croatia
700    1_
$a Marin, Alexandru $u Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania
700    1_
$a Husa, Petr $u University Hospital Brno, Masaryk University, Brno, Czechia
700    1_
$a Nicolay, Nathalie $u European Centre for Disease Prevention and Control, Stockholm, Sweden
700    1_
$a Rose, Angela M C $u Epiconcept, Paris, France $1 https://orcid.org/0000000224938082
710    2_
$a VEBIS SARI VE network team
773    0_
$w MED00157838 $t Influenza and other respiratory viruses $x 1750-2659 $g Roč. 19, č. 3 (2025), s. e70081
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40059069 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135119 $b ABA008
999    __
$a ok $b bmc $g 2311154 $s 1246686
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 19 $c 3 $d e70081 $e - $i 1750-2659 $m Influenza and other respiratory viruses $n Influenza Other Respir Viruses $x MED00157838
GRA    __
$a ECDC/2021/016 (EU-H) $p European Centre for Disease Prevention and Control
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace